High SVR rates found with AbbVie's Viekirax and Exviera for hepatitis C – regardless of variants

14 April 2016

US pharma major AbbVie (NYSE: ABBV) presented new data on Thursday on patients with genotype 1 chronic hepatitis C virus (HCV) infection who took Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir).

Treated with or without ribavirin (RBV), they achieved high sustained virologic response rates at 12 weeks post-treatment (SVR12), regardless of the presence of baseline resistance-associated variants (RAVs).

The data comes from a post-hoc analysis of five completed Phase III clinical trials and was presented at The International Liver Congress 2016 in Barcelona. It was found that no matter whether certain RAVs, called NS5A, were present, all 148 of patients with genotype 1b chronic HCV infection, who received Viekirax and Exviera without RBV for 12 weeks, achieved SVR12.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK